Matthias J Schnell Selected Research

Pattern Recognition Receptors

7/2010

Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthias J Schnell Research Topics

Disease

25	Rabies (Hydrophobia) 01/2022 - 04/2002
19	Infections 01/2019 - 01/2002
12	Vesicular Stomatitis 07/2021 - 04/2003
8	Communicable Diseases (Infectious Diseases) 01/2022 - 04/2003
5	Virus Diseases (Viral Diseases) 12/2016 - 01/2002
4	COVID-19 01/2022 - 01/2020
3	Weight Loss (Weight Reduction) 01/2022 - 01/2015
3	Neoplasms (Cancer) 05/2015 - 07/2008
3	Neuroblastoma 01/2011 - 12/2005
2	Inflammation (Inflammations) 01/2022 - 12/2005
2	Lung Diseases (Lung Disease) 01/2022 - 01/2021
2	Lassa Fever (Fever, Lassa) 01/2021 - 10/2018
2	Emerging Communicable Diseases (Emerging Infectious Diseases) 01/2020 - 01/2017
2	Anthrax 08/2010 - 09/2006
2	Acquired Immunodeficiency Syndrome (AIDS) 12/2009 - 04/2007
2	Neoplasm Metastasis (Metastasis) 04/2009 - 07/2008
2	Colorectal Neoplasms (Colorectal Cancer) 04/2009 - 07/2008
2	Hepatitis C 01/2003 - 01/2002
1	Measles 04/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Cytokine Release Syndrome 01/2022
1	Asymptomatic Infections 01/2021
1	Marburg Virus Disease 01/2019
1	Viral Hemorrhagic Fevers (Viral Hemorrhagic Fever) 10/2018
1	Zoonoses 01/2017
1	Henipavirus Infections 01/2015
1	Fever (Fevers) 07/2014
1	Central Nervous System Diseases (CNS Diseases) 01/2012
1	Intestinal Neoplasms (Intestinal Cancer) 04/2009
1	Colonic Neoplasms (Colon Cancer) 04/2009
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 04/2009
1	Carcinogenesis 04/2009

Drug/Important Bio-Agent (IBA)

40	VaccinesIBA 04/2022 - 01/2002
10	Glycoproteins (Glycoprotein)IBA 01/2020 - 01/2002
8	Proteins (Proteins, Gene)FDA Link 01/2017 - 09/2003
5	Neutralizing AntibodiesIBA 01/2022 - 12/2009
5	Antiviral Agents (Antivirals)IBA 01/2019 - 06/2003
4	GTP-Binding Proteins (G-Protein)IBA 01/2020 - 12/2006
4	AntigensIBA 01/2019 - 09/2006
3	AntibodiesIBA 04/2022 - 11/2008
3	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 06/2003
3	Combined VaccinesIBA 01/2017 - 10/2011
2	COVID-19 VaccinesIBA 01/2022 - 01/2020
2	SARS-CoV-2 spike proteinIBA 01/2022 - 07/2021
2	CoraVax COVID-19 vaccineIBA 01/2022 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2020 - 11/2008
2	Ebola VaccinesIBA 01/2019 - 02/2015
2	Rabies Vaccines (Rabies Vaccine)FDA Link 10/2018 - 06/2003
2	Codon (Codons)IBA 01/2015 - 01/2011
2	Inactivated VaccinesIBA 10/2011 - 06/2004
2	Interferon Type IIBA 07/2010 - 12/2009
2	Enterotoxin ReceptorsIBA 04/2009 - 07/2008
2	Viral RNAIBA 11/2008 - 07/2007
1	Pharmaceutical PreparationsIBA 01/2020
1	Molecular Probes (Molecular Probe)IBA 01/2020
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2017
1	Attenuated VaccinesIBA 05/2015
1	InflammasomesIBA 05/2013
1	Viral AntigensIBA 01/2012
1	MicroRNAs (MicroRNA)IBA 01/2011
1	Pattern Recognition ReceptorsIBA 07/2010
1	Immunotoxins (Immunotoxin)IBA 02/2010
1	SilverIBA 06/2009
1	AutoantigensIBA 04/2009
1	Viral VaccinesIBA 11/2008
1	A-factor (Streptomyces)IBA 04/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2005
1	Chemokine CCL5IBA 01/2002

Therapy/Procedure

3	Therapeutics 05/2015 - 06/2003
2	Immunotherapy 04/2009 - 07/2008